A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of SHR4640 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 01 Apr 2017
At a glance
- Drugs SHR 4640 (Primary)
- Indications Gout; Hyperuricaemia
- Focus Adverse reactions
- Sponsors Jiangsu Hengrui Medicine Co.
- 29 Mar 2017 Status changed from recruiting to completed.
- 26 Feb 2017 Planned End Date changed from 1 Dec 2016 to 1 Mar 2016.
- 22 Sep 2016 New trial record